Search Orphan Drug Designations and Approvals
-
Generic Name: | a humanized IgG1kappa-agonistic anti-CD40 mAb |
---|---|
Date Designated: | 08/03/2021 |
Orphan Designation: | Treatment of patients with Soft Tissue Sarcoma (STS). |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Pyxis Oncology, Inc. 321 Harrison Avenue 11th Floor, Suite 1 Boston, Massachusetts 02118 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-